We are live on ! Find out more
ICPT

Intercept Pharmaceuticals, Inc.

Delisted

ICPT was delisted on the 7th of November, 2023.

188 hedge funds and large institutions have $1.6B invested in Intercept Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 56 increasing their positions, 71 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less call options, than puts

Call options by funds: $79.6M | Put options by funds: $79.9M

13% less funds holding

Funds holding: 215188 (-27)

21% less repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 71

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

47% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 49

50% less capital invested

Capital invested by funds: $3.2B → $1.6B (-$1.6B)

Holders
188
Holders Change
-27
Holders Change %
-12.56%
% of All Funds
4.14%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
26
Increased
56
Reduced
71
Closed
49
Calls
$79.6M
Puts
$79.9M
Net Calls
-$332K
Net Calls Change
+$49.4M

ICPT Hedge Fund Activity: Q1 2020 in Review

188 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2020, worth a combined $1.6B — down 50% from $3.2B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ICPT and 26 opened new positions — a net loss of 23 holders — while 71 trimmed existing stakes and 56 added.

The largest buyer was Sarissa Capital Management, adding an estimated $26.5M. The largest seller was Wellington Management Group, exiting entirely with an estimated $33.8M sold.

  • 188 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2020, down from 215 in Q4 2019.
  • Funds reported $1.6B of Intercept Pharmaceuticals, Inc. stock for Q1 2020, down 50% quarter-over-quarter.
  • 26 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2020 and 49 closed out, a net change of -23 holders.
  • The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2020 was Sarissa Capital Management, an estimated $26.5M added.
  • The largest Intercept Pharmaceuticals, Inc. seller in Q1 2020 was Wellington Management Group, an estimated $33.8M sold.

Based on aggregated 13F filings for Q1 2020.